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I NTROD UCTION 
To put the subjects of biliary atresia and liver transplantation into perspective, 
I will first discuss our total case material, summarize our results in all pediatric 
recipients, and fmally focus upon the subset of patients with biliary atresia. 
The first long-term survival after liver replacement was a dog whose new liver 
came from a nonrelated mongrel donor in 1963. The animal lived a full canine 
lifetime, finally dying of old age almost 12 years later. That longevity record has 
now been superseded by a girl with biliary atresia who was given a new liver 12 
years ago and is now in high school. When her diseased liver was sectioned after 
its removal, we were stunned to find a 2-cm hepatoma. Serum a-fetoprotein was 
about 6 mg %. No tumor recurrences have been seen in the intervening years. 
CLINICAL TECHNICAL CONSIDERATIONS 
The procedure of orthotopic liver transplantation consists of removal of the 
diseased native liver and its replacement with the liver of a cadaveric donor. This 
is now an easier undertaking partly because of the widespread acceptance of brain 
death in the United States. One can preserve livers relatively safely for about 8 h 
with good expectation of a successful transplantation. This development in preser-
vation relieved the logistic burdens from which we were previously suffering, 
whereby it was necessary or bighly desirable to have the donor and recipient in 
the same hospital and, hopefully, in adjacent operating rooms. Now it is quite 
possible to collect a liver in a community hospital and transplant it in a distant 
major medical center (1). 
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The recipient operation for the placement of a new liver is very straightforward. 
It consists of an anastomosis of the inferior vena cava above and below the liver 
and the reconstruction of the portal triad structures. The ideal form of biliary 
tract reconstruction is with a duct-to-duct anastomosis, but in patients with biliary 
atresia that obviously is not feasible. In the early days, we often ligated the distal 
common duct of the homograft and anastomosed the gallbladder to the duodenum. 
This was a procedure of convenience, but it proved disastrous. In recent years, 
despite the smallness of the common duct of the pediatric livers, we have anasto-
mosed the common duct directly into a Roux limb of jejunum. This solution to 
biliary drainage is more satisfactory, in most cases, than the alternative of connecting 
the gallbladder into the defunctionalized Roux limb (1). 
When we first began treating patients who had previously undergone Kasai 
operations, the Roux limbs were uninterrupted by ostomy side vents, which have 
since become common. The Roux limbs could usually be reused at the time of 
transplantation. With the more complicated Kasai procedures in which skin 
jejunostomies have been constructed (and often closed later), it has almost always 
been necessary to take down the Roux limb, often with difficulty, and to begin 
over. Thus, as worthwhile as it is, the Kasai operation does pose certain technical 
difficulties for eventual transplantation. 
ADULT AND PEDIATRIC CASES {1963-1979} 
The end of 1979 concluded an era in which patients were treated with the conven-
tional immunosuppression, consisting of azathioprine, prednisone, and often anti-
lymphocytic globulin (ALG). There were 169 recipients, of whom 86 were 18 
years or younger. An almost equal number (83 patients) were adults, whose 
indications for operation are summarized in Table 1. Cluonic active hepatitis was 
the most common hepatic disorder in the adults. 
Table 1 Indications for Transplantation: 1963-1979 (Adults 19-70 Years) 
Chronic active hepatitis 32 
Primary liver malignancy 
Alcoholic cirrhosis 
Primary biliary cirrhosis 
Sclerosing cholangitis 
Secondary biliary cirrhosis 
Massive hepatic necrosis (B virus) 
Budd-Chiari syndrome 
Protoporphyria 
Total 
16 
16 
7 
6 
3 
83 
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During the same 16-and-2/3-year period, 86 patients in the pediatric category 
were treated with orthotopic liver transplantation (Table 2). There were 53 cases 
of biliary atresia, four times as common an indication as the next most common 
category, inborn errors of metabolism. Twelve pediatric recipients had chronic 
active hepatitis (Table 2). Immunosuppressive therapy was similar in adults and 
children and was adapted from treatment protocols which were standardized with 
simpler renal transplantation models. With azathioprine, prednisone, and ALG, 
while it was possible to succeed in some cases of liver transplantation, there was 
very little margin of safety and loss rates were unacceptable. The actual life 
survival curves from 1963 to the end of 1979 are summarized in Figure 1. In our 
original series (the first long-term survival was achieved in 1967), about two-thirds 
of the patients died by the end of the first postoperative year. In a second, smaller 
series in which many improvements in techniques and management were instituted, 
the I-year survival rose to 50%, but this proved to be a fluke. In the third series 
which followed, the data once again were similar to those of the original group. 
This was an unsatisfactory situation, which caused many people to wonder if such 
extreme efforts as those that were required in these trials could be further justified. 
During those lean years, 16 (30.2%) of the 53 patients with biliary atresia 
lived for as long as I year (Table 3). The one justifying aspect of the undertaking 
was that eight of those survivors are still living after 4-12 years. During the same 
time, when the 53 patients with biliary atresia were observed, 33 pediatric re-
cipients with other hepatic disorders were treated at the University of Colorado. 
The I-year survival of the biliary atresia patients of 30.2% was distinctly inferior 
to that achieved in children who had other diagnoses, of whom more than half 
were alive at the end of the first postoperative year (Table 3). Subsequent to a 
year, the advantage of having diagnoses other than biliary atresia has persisted 
(Table 3). Today only about one in seven (15%) of the biliary atresia recipients 
are still living (Table 3). 
Table 2 Indications for Transplantation: 1963-1979 E~ 18 Years) 
Biliary atresia 53 
Inborn metabolic errors 
Chronic active hepatitiS 
Hepatoma 
Neonatal hepatitis 
Congenital biliary cirrhosis 
Congenital hepatic fibrosis 
Secondary biliary cirrhosis 
Total 
aInborn errors: a1-antitrypsin,9; Wilson's Disease, 2; tyrosinemia, 1; 
type IV GSD, 1. 
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Figure lOne-year actuarial survival in patients given liver transplants. The 
follow-up period ranged from 8 to 14% months. The open circles represent sur-
vival in the 12 patients who lived through the operation and who were treated 
with Cyclosporin A and prednisone; the solid circles represent survival in all 14 
patients who underwent transplantation (including the 2 who died during the 
operation); and the crosses represent survival in 170 patients from a previous 
series who were treated with conventional immunosuppression. (Modified from 
Ref. 9 by permission of the New England Journal of Medicine 305:266, 1981.) 
EMERGENCE OF CYCLOSPORIN A 
After laboring in these barren vineyards for many years, it was our conclusion 
that there was virtually no margin of safety with liver transplantation under 
conventional immunosuppression. We were constantly on the lookout for 
improvements in immunosuppression, and such an improvement came to light in 
1976 in a journal called Agents and Actions. Borel and his associates of the 
Sandoz Corporation, Basel, Switzerland, had done a magnificent job of character-
Table 3 Pediatric Transplantation: 1963-1979 
Number 
Biliary atresia 53 
Other diseases 33 
a4_12 years. 
b 2_11 years. 
I-year survival 
16 (30.2%) 
17 (51.6%) 
Alive now 
8 (15.1%)3 
12 (36.4%)b 
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izing cyclosporin A and its immunosuppressive qualities, including specific testing 
of skin grafts in rats (2). Furthermore, Sandoz chemists fully characterized the 
structure of this agent almost at the outset. The agent was released for limited 
animal work in 1977 and 1978, for clinical trial in Britain in 1978 (3), and at 
two centers in the United States in 1979. The first American clinical trials were 
at the University of Colorado and at the Peter Bent Brigham Hospital in Boston. 
Results with cyclosporin A were profoundly encouraging in some centers, but 
not in others. At Cambridge, England (4), and in Colorado (5,6), the survival of 
primary cadaveric kidney recipients was exceptionally high, 80% or better, but 
at the Peter Bent Brigham Hospital (7) and at the Royal Free Hospital in London 
(8) the results were disappointing. We think that the reason for our success with 
cyclosporin was its combination with low doses of steroid (5,6). 
CYCLOSPORIN A-STEROID THERAPY AND 
LIVER TRANSPLANTATION 
After 25 kidney recipients had been treated with the combination of cyclosporin 
A plus steroids, a decision was made to use this therapy for adult liver recipients. 
The dose of cyclosporin A (17.5 mg/kg per day) was combined with variable 
dosages of prednisone, usually in the range of 20 mg/day. For the first time, it 
became possible to effectively control liver rejection without a tremendous penalty 
in terms of chronic high-dose steroid therapy. 
Cyclosporin had been forbidden for clinical use in patients under 18 years of 
age, but by agreement with the drug company and the Food and Drug Adminis-
tration, we were empowered to do the first trials with this agent in pediatric 
patients. These were liver as well as kidney recipients whose sera contained such 
widely reacting T-warm cytotoxic antibodies that they were considered untreatable 
under conventional circumstances. With this experience, we now realize that the 
supreme value of cyclosporin A will be for pediatric patients whose growth and 
development no doubt would be impeded by chronic high dose steroid therapy. 
We entered 14 patients into a potential cyclosporin trial. Two of these patients 
died on the operating table. Of the 12 patients who could be treated with cyclo-
sporin and low-dose steroids, only 1 failed to survive the first postoperative year. 
The 1-year survival of those actually treated was 92% (9). Even including the 
two unfortunate operative deaths, the I-year survival of the liver recipients was 
almost 80%. These results were better than our entire historical experience with 
liver transplantation using standard immunosuppression (Fig. 1). 
Since arriving in Pittsburgh, we have treated an additiona121 patients. These 
patients, combined with the 14 earlier Colorado cases, give us 34. The indications 
for operation are listed in Table 4. Of the 34 cases, there were 22 adults, 14 of 
whom are still alive. There were 12 pediatric cases, of whom 10 are alive (Table 5). 
The only deaths in this group were due to technical problems. One of the two 
patients, a child with Byler's syndrome, had a lwpatic artery thrombosis. The 
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Table 4 Liver Transplantation in the Cyc1osporin Era: 1980-1981 
Chronic active hepatitis 8 
Primary hepatic malignancy 
(three hepatoma, one Klatskin) 
Biliary atresia 
a l -Antitrypsin deficiency 
Budd-Chiari syndrome 
Secondary biliary cirrhosis 
Primary biliary cirrhosis 
Sclerosing cholangitis 
(one with duct cell carcinoma) 
Congenital hepatic fibrosis 
Byler's syndrome 
Wilson's disease 
Total 
4 
4 
4 
3 
3 
2 
2 
2 
1 
34 
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other death was in a child with a l -antitrypsin deficiency. His choledochojejunostomy 
anastomosis apparently leaked, creating an abscess which eroded into the portal vein. 
In children with biliary atresia, four of four survive, the longest follow-up being 
well over a year (Table 5). 
In the pediatric cases, 83% of all children treated with cyclosporin are living, 
going back almost 2 years. The results make it look as if a new era has arrived in 
liver transplantation. 
Editors' note: The evolution of liver transplantation, issues evolved and the 
most recent survival data have been updated since this symposium (1). 
Table 5 Pediatric Cases of Liver Transplantation in the Cyclosporin Era 
Biliary atresia 
aI-Antitrypsin 
Congenital hepatic fibrosis 
Neonatal hepatitis 
Wilson's disease 
Budd-Chiari syndrome 
Byler's syndrome 
Total 
Number 
4 
3 
12 
aFoliow-up after 1-15 months. The deaths were caused by (1) hepatic artery 
thrombosis and (2) biliary anastomosis leak and abscess. 
4 
2 
1 
1 
o 
10 
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